Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMA Grants Waivers To Test StemEx From Gamida Cell-Teva JV
StemEx is being developed by a joint venture equally owned and operated by Gamida Cell and Teva Pharmaceuticals. Moreover, a company has to submit to the PDCO a
StemEx is being developed by a joint venture equally owned and operated by Gamida Cell and Teva Pharmaceuticals. Moreover, a company has to submit to the PDCO a
Medpace opines that Medical Consulting will add strategic expertise in terms of providing centralized European hubs for regulatory submissions and approvals as well as drug safety management and
Phylogica has already demonstrated lead peptide compounds that bind with high affinity and are biologically active against CD40L. Isogenica’s CIS display technology allows a comprehensive search process to
During the evaluation period, AstraZeneca will assess the performance of the Flexyte platform in its laboratories against specific targets of interest. Stephen Barr, president and managing director of
The company claims that Alpharadin is a targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced prostate cancer. Its localised action helps
Theratechnologies, a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics, has said that the meeting will take place at the Hilton Washington DC/Silver Spring (8727 Colesville Road,
As per the agreement, the companies are expected to work together to develop diagnostic tests to help physicians determine the most appropriate cancer treatment for patients. The financial
As per the agreement, the companies are expected to work together to develop diagnostic tests to help physicians determine the most appropriate cancer treatment for patients. The collaboration
Alli 60mg capsule is indicated for weight loss in overweight adults, 18 years and older, when used along with a reduced-calorie, low-fat diet. Preliminary laboratory tests conducted by
Takeda, the originator of Actos, said that it helps reduce insulin resistance. In Japan, Actos tablets were approved and launched in 1999, and a New Drug Application for